134 related articles for article (PubMed ID: 25586350)
1. Adiponectin inhibits VEGF-A in prostate cancer cells.
Gao Q; Zheng J; Yao X; Peng B
Tumour Biol; 2015 Jun; 36(6):4287-92. PubMed ID: 25586350
[TBL] [Abstract][Full Text] [Related]
2. MiR-323 Inhibits Prostate Cancer Vascularization Through Adiponectin Receptor.
Gao Q; Yao X; Zheng J
Cell Physiol Biochem; 2015; 36(4):1491-8. PubMed ID: 26160610
[TBL] [Abstract][Full Text] [Related]
3. [Vascular endothelial growth factor in patients with prostate cancer and benign prostatic hyperplasia].
Trapeznikova MF; Shibaev AN; Kazantseva IA; Mironova OS; Gurevich LE; Morozov AP; Urenkov SB; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 2005; (5):14-6. PubMed ID: 15960197
[TBL] [Abstract][Full Text] [Related]
4. Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells.
Yu HS; Wang SW; Chang AC; Tai HC; Yeh HI; Lin YM; Tang CH
Biochem Pharmacol; 2014 Jan; 87(2):243-53. PubMed ID: 24225154
[TBL] [Abstract][Full Text] [Related]
5. Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-α pathway.
Lee HP; Lin CY; Shih JS; Fong YC; Wang SW; Li TM; Tang CH
Oncotarget; 2015 Nov; 6(34):36746-61. PubMed ID: 26468982
[TBL] [Abstract][Full Text] [Related]
6. Role of Adiponectin in prostate cancer.
Hu X; Hu C; Zhang C; Zhang M; Long S; Cao Z
Int Braz J Urol; 2019; 45(2):220-228. PubMed ID: 30648824
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF-kappaB pathways.
Tang CH; Lu ME
Prostate; 2009 Dec; 69(16):1781-9. PubMed ID: 19676095
[TBL] [Abstract][Full Text] [Related]
8. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study.
Michalakis K; Williams CJ; Mitsiades N; Blakeman J; Balafouta-Tselenis S; Giannopoulos A; Mantzoros CS
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):308-13. PubMed ID: 17301264
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
Ling MT; Lau TC; Zhou C; Chua CW; Kwok WK; Wang Q; Wang X; Wong YC
Carcinogenesis; 2005 Oct; 26(10):1668-76. PubMed ID: 15905202
[TBL] [Abstract][Full Text] [Related]
10. Globular adiponectin protects human umbilical vein endothelial cells against apoptosis through adiponectin receptor 1/adenosine monophosphate-activated protein kinase pathway.
Zhao HY; Zhao M; Yi TN; Zhang J
Chin Med J (Engl); 2011 Aug; 124(16):2540-7. PubMed ID: 21933602
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the AMPK/mTOR pathway.
Zhan JK; Wang YJ; Wang Y; Tang ZY; Tan P; Huang W; Liu YS
Exp Cell Res; 2014 May; 323(2):352-8. PubMed ID: 24607448
[TBL] [Abstract][Full Text] [Related]
12. Aromatic hydrocarbon receptor inhibits lysophosphatidic acid-induced vascular endothelial growth factor-A expression in PC-3 prostate cancer cells.
Wu PY; Lin YC; Lan SY; Huang YL; Lee H
Biochem Biophys Res Commun; 2013 Aug; 437(3):440-5. PubMed ID: 23831623
[TBL] [Abstract][Full Text] [Related]
13. Antofine, a natural phenanthroindolizidine alkaloid, suppresses angiogenesis via regulation of AKT/mTOR and AMPK pathway in endothelial cells and endothelial progenitor cells derived from mouse embryonic stem cells.
Oh J; Kim GD; Kim S; Lee SK
Food Chem Toxicol; 2017 Sep; 107(Pt A):201-207. PubMed ID: 28666888
[TBL] [Abstract][Full Text] [Related]
14. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response.
Shimano M; Ouchi N; Shibata R; Ohashi K; Pimentel DR; Murohara T; Walsh K
J Mol Cell Cardiol; 2010 Aug; 49(2):210-20. PubMed ID: 20206634
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.
Chang WL; Hsu LC; Leu WJ; Chen CS; Guh JH
Oncotarget; 2015 Nov; 6(37):39806-20. PubMed ID: 26447757
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
18. Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo.
Weiss TW; Simak R; Kaun C; Rega G; Pflüger H; Maurer G; Huber K; Wojta J
Anticancer Res; 2011 Oct; 31(10):3273-8. PubMed ID: 21965736
[TBL] [Abstract][Full Text] [Related]
19. A potential autocrine role for vascular endothelial growth factor in prostate cancer.
Jackson MW; Roberts JS; Heckford SE; Ricciardelli C; Stahl J; Choong C; Horsfall DJ; Tilley WD
Cancer Res; 2002 Feb; 62(3):854-9. PubMed ID: 11830543
[TBL] [Abstract][Full Text] [Related]
20. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
Koul D; Shen R; Garyali A; Ke LD; Liu TJ; Yung WK
Int J Oncol; 2002 Sep; 21(3):469-75. PubMed ID: 12168088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
